-
Reassessment of reimbursement status for medicinal products in ATC group C08CA
| 29 October 2008 |
The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.
All items (457)
-
Time
- 2024 (18)
- 2023 (24)
- 2022 (20)
- 2021 (44)
- 2020 (62)
- 2019 (20)
- 2018 (37)
- 2017 (54)
- 2016 (53)
- 2015 (11)
- 2014 (13)
- 2013 (11)
- 2012 (11)
- 2011 (13)
- 2010 (9)
- 2009 (14)
- 2008 (7)
- 2007 (3)
- 2006 (10)
- 2023 (24)
- 2024 (18)
- 2011 (13)
- 2013 (11)
- 2014 (13)
- 2015 (11)
- 2016 (53)
- 2017 (54)
- 2018 (37)
- 2019 (20)
- 2020 (62)
- 2021 (44)
- 2022 (20)
- 2006 (10)
- 2009 (14)
- 2010 (9)
- 2007 (3)
- 2012 (11)
- 2008 (7)
- 2021 (44)
- 2022 (20)
- 2023 (24)
- 2024 (18)
- 2010 (9)
- 2011 (13)
- 2012 (11)
- 2015 (11)
- 2016 (53)
- 2017 (54)
- 2018 (37)
- 2019 (20)
- 2020 (62)